-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"2021 Beijing Urinary Oncology Youth Forum and Year-end Inventory of Urinary Oncology" was held on January 10 in the form of an online + live conference.
During the meeting, Professor Yu Wei from Peking University First Hospital summarized the progress of prostate cancer in China in 2020.
Professor Yu Wei, Chief Physician, Department of Urology, Peking University First Hospital, Member of the Standing Committee of the Urothelial Cancer Committee of the Chinese Society of Clinical Oncology, Member of the Oncology Group of the Urology Committee of the Chinese Society of Integrative Medicine, Member of the Urogenital Oncology Group of the Anti-Cancer Association Family Genetic Tumor Collaboration Group, China Member of the Youth Committee of the Kidney Transplant Branch of the Health Care International Exchange Promotion Association Member of the CUA Urinary Control Young Physician Alliance This article summarizes the literature published by Chinese scholars in the field of prostate cancer in 2020, showing that Chinese scholars’ research in the field of prostate cancer is increasingly receiving international attention.
The attention of academia.
From January 1, 2020 to December 10, 2019, Chinese scholars have published a total of 1,359 articles in the field of prostate cancer.
The top 5 research institutions are Shanghai Jiaotong University, Sichuan University, Sun Yat-sen University, China Medical University and Zhejiang University.
The most numerous are FRONTIERS IN ONCOLOGY magazines, among which there are many journals with high impact factors.
A great harvest in prostate cancer basic research.
Gao Xu, Sun Yinghao, Shanghai Changhai Hospital, etc.
Research published in Nature: A genomic and epigenomic altas of prostate cancer in Asian populations.
Gao Dong, Chinese Academy of Sciences Research published in Nature Genetics: Single -cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips Chinese Academy of Sciences Jun Qin, Daping Hospital Jiang Jun, etc.
Research published in Cancer Cell: SETD2 Restricts prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways published by Gao Dong, Chinese Academy of Sciences Research in J Clin Invest magazine: ERG orchestrates chromatin interaction to drive prostate cell fate reprogramming Southern Medical University Huang Wenhua et al.
Research in J Clin Invest magazine: Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
Shanghai Tongji Hospital Wu Qiang, Wu Denglong and others published a study in Mol Cell: DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1 Xie Liping, First Affiliated Hospital of Zhejiang University School of Medicine, published in EU Journal Research: CDKI2 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype.
Research by Zhu Qingyi, Jiangsu Provincial Hospital of Traditional Chinese Medicine and others published in Cancer Research: Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance Qilu Hospital Han Bo Research published in Cancer Research: KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer Department of Wuhan Union Medical College Hospital, Zhang Xiaoping, Research published in Clinical Cancer Research: Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Prostate Cancer: Epidemiology The First Affiliated Hospital of Zhejiang University School of Medicine Dai Zhijun et al.
Research published in CANCER: Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study2017.
Research by Mao Yingying from Zhejiang University of Traditional Chinese Medicine published in INTERNATIONAL JOURNAL OF CANCER: Genetically predicted levels of circulating cytokines and prostate cancer risk: A Mendelian randomization study.
Prostate cancer: Diagnostic studies Zhu Yao, Ye Dingwei, Affiliated Tumor Hospital of Fudan University, etc.
, published in Clinical Cancer Research: A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration.
Shanghai Changhai Hospital Wang Haifeng and others published in ANNALS OF SURGICAL ONCOLOGY: A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
West China Hospital Zeng Hao, Shen Peng, etc.
Research published in Asian J Androl: Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Prostate cancer: clinical research Zhang Xu from the General Hospital of the People’s Liberation Army, Liao Limin from the China Rehabilitation Center, etc.
Research published in BMC Urol: Urinary continence outcomes of four years of follow-up and predictors of early and late urinary continence in patients undergoing robot-assisted radical prostatectomy.
Wang Gongxian, First Affiliated Hospital of Nanchang University, published in BJU Int Journal: Transvesical robot-assisted radical prostatectomy: initial experience and surgical outcomes.
Shanghai Changhai Hospital Sun Yinghao published in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key Recommendations Key Recommendation 1: Gao Xu, Sun Yinghao, Shanghai Changhai Hospital: Genetic changes and epigenetic profile of prostate cancer in Asian population.
Sun Yinghao, Shanghai Changhai Hospital, published a study in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key Recommendation 1: Shanghai Changhai Hospital Gao Xu and Sun Yinghao: Asian Human prostate cancer genetic changes and epigenetic map.
Sun Yinghao, Shanghai Changhai Hospital, published a study in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key recommendation1: Shanghai Changhai Hospital Gao Xu and Sun Yinghao: Asian Human prostate cancer genetic changes and epigenetic map. The team of Professor Gao Xu and Sun Yinghao from Changhai Hospital drew and analyzed the whole genome, whole transcriptome and DNA methylation data of 208 pairs of tumor tissue samples, and matched the healthy control tissues of Chinese patients with primary prostate cancer.
The genetic and epigenetic profile of prostate cancer in the ethnic population.
The study found that the characteristics of genomic changes in Chinese patients are significantly different from those in western patients.
In particular, it should be pointed out that FOXA1 is highly expressed in the Chinese population (41%), and 18% of tumors ZNF292 and CHD1 are missing.
This research provides a certain reference basis for future drug development and tumor heterogeneity.
Key recommendation 2: 4 articles related to the pathogenesis of prostate cancer published by Chinese scholars in 2020.
The 4 blockbuster studies on the pathogenesis and origin of prostate cancer have all been highly recognized internationally, with a score of 20-30 in journals.
Key recommendation 3: Research on the drug resistance mechanism of potent androgen receptor blockers.
In the research published by clinicians, the focus is mainly on the treatment of new drugs, the drug resistance mechanism and the corresponding targeted therapies for related mechanisms, all of which have been obtained domestically Highly recognized by peers.
These studies provide a new perspective on the mechanism of AR blocker resistance.
Key recommendation 4: Clinical research The West China Hospital team, led by Professor Wei Qiang and Professor Zeng Hao, has been engaged in a series of studies on prostate intraductal carcinoma for a long time.
A series of articles have been published.
Last year’s research results were published in JEU.
This year, the researchers further revealed through a prospective cohort study that for patients undergoing radical prostatectomy, the pathology of preoperative prostate puncture has intraductal cancer and the final surgical pathology Gleason score.
8-10.
Seminal vesicle involvement, pathological stage T3a and other high-risk and highly aggressive characteristics of prostate cancer are related, which can be used to predict the time for high-risk patients without biochemical recurrence after surgery.
Robot-assisted radical prostatectomy has been widely carried out in recent years, but reports of long-term postoperative urinary incontinence are still rare.
Professor Zhang Xu from the General Hospital of the People’s Liberation Army and Professor Liao Limin from the China Rehabilitation Center announced the urinary incontinence of patients 4 years after the robot-assisted radical prostatectomy.
This study is the largest urinary control data on radical treatment of prostate cancer in China so far.
More than 600 patients were included and the follow-up time was close to 4 years.
The results showed that the one-month urinary control rate was 40%, and the three-month urinary control rate reached 60%.
Patients with early postoperative urinary incontinence can gradually recover within one year.
Data show that pelvic lymph node dissection is a risk factor for early postoperative urinary incontinence, advanced age is a risk factor for long-term postoperative urinary incontinence, and intrafascial nerve preservation surgery is still the most important means to improve urinary control.
Key recommendation 5: Clinical research In clinical research, there are two studies in Fudan University Affiliated Cancer Hospital that are worthy of attention: Professor Zhu Yao’s team has carried out the use of 68Ga-PSMA and 18F-FDG PET/CT dual imaging agents in prostate cancer to observe tumors Heterogeneity research.
Professor Ye Dingwei and Professor Dai Bo announced on ESMO the “randomized controlled open-label phase 2 clinical study of newly diagnosed oligometastatic prostate cancer receiving local treatment of the primary tumor”.
This study is the first prospective randomized controlled study to explore the clinical value of radical prostatectomy in patients with newly diagnosed oligometastatic prostate cancer.
A total of 200 patients were enrolled in the study, and they were randomly assigned to the endocrine therapy group (ADT group) and the endocrine therapy combined with the radical treatment group (ADT+RLT group) at 1:1.
The results showed that at a median follow-up of 28 months, 33 patients in the ADT group developed imaging disease progression, 19 patients in the ADT+RLT group developed imaging disease progression, and the median rPFS of the ADT group was 50 months.
The median rPFS of the ADT+RLT group was not reached, and the treatment of the primary tumor of oligometastatic prostate cancer significantly reduced the risk of imaging disease progression in patients (HR=0.
50, P=0.
015).
At present, relevant clinical research in the field of prostate cancer is being extensively carried out in China, including the relevant research of the new androgen receptor antagonist proclutamide, Hc-1119 and PARP inhibitors.
It is believed that the basic and clinical research in the field of prostate will achieve better results in the future.
As a result, a higher level is reached.
During the meeting, Professor Yu Wei from Peking University First Hospital summarized the progress of prostate cancer in China in 2020.
Professor Yu Wei, Chief Physician, Department of Urology, Peking University First Hospital, Member of the Standing Committee of the Urothelial Cancer Committee of the Chinese Society of Clinical Oncology, Member of the Oncology Group of the Urology Committee of the Chinese Society of Integrative Medicine, Member of the Urogenital Oncology Group of the Anti-Cancer Association Family Genetic Tumor Collaboration Group, China Member of the Youth Committee of the Kidney Transplant Branch of the Health Care International Exchange Promotion Association Member of the CUA Urinary Control Young Physician Alliance This article summarizes the literature published by Chinese scholars in the field of prostate cancer in 2020, showing that Chinese scholars’ research in the field of prostate cancer is increasingly receiving international attention.
The attention of academia.
From January 1, 2020 to December 10, 2019, Chinese scholars have published a total of 1,359 articles in the field of prostate cancer.
The top 5 research institutions are Shanghai Jiaotong University, Sichuan University, Sun Yat-sen University, China Medical University and Zhejiang University.
The most numerous are FRONTIERS IN ONCOLOGY magazines, among which there are many journals with high impact factors.
A great harvest in prostate cancer basic research.
Gao Xu, Sun Yinghao, Shanghai Changhai Hospital, etc.
Research published in Nature: A genomic and epigenomic altas of prostate cancer in Asian populations.
Gao Dong, Chinese Academy of Sciences Research published in Nature Genetics: Single -cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips Chinese Academy of Sciences Jun Qin, Daping Hospital Jiang Jun, etc.
Research published in Cancer Cell: SETD2 Restricts prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways published by Gao Dong, Chinese Academy of Sciences Research in J Clin Invest magazine: ERG orchestrates chromatin interaction to drive prostate cell fate reprogramming Southern Medical University Huang Wenhua et al.
Research in J Clin Invest magazine: Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
Shanghai Tongji Hospital Wu Qiang, Wu Denglong and others published a study in Mol Cell: DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1 Xie Liping, First Affiliated Hospital of Zhejiang University School of Medicine, published in EU Journal Research: CDKI2 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype.
Research by Zhu Qingyi, Jiangsu Provincial Hospital of Traditional Chinese Medicine and others published in Cancer Research: Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance Qilu Hospital Han Bo Research published in Cancer Research: KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer Department of Wuhan Union Medical College Hospital, Zhang Xiaoping, Research published in Clinical Cancer Research: Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Prostate Cancer: Epidemiology The First Affiliated Hospital of Zhejiang University School of Medicine Dai Zhijun et al.
Research published in CANCER: Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study2017.
Research by Mao Yingying from Zhejiang University of Traditional Chinese Medicine published in INTERNATIONAL JOURNAL OF CANCER: Genetically predicted levels of circulating cytokines and prostate cancer risk: A Mendelian randomization study.
Prostate cancer: Diagnostic studies Zhu Yao, Ye Dingwei, Affiliated Tumor Hospital of Fudan University, etc.
, published in Clinical Cancer Research: A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration.
Shanghai Changhai Hospital Wang Haifeng and others published in ANNALS OF SURGICAL ONCOLOGY: A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
West China Hospital Zeng Hao, Shen Peng, etc.
Research published in Asian J Androl: Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Prostate cancer: clinical research Zhang Xu from the General Hospital of the People’s Liberation Army, Liao Limin from the China Rehabilitation Center, etc.
Research published in BMC Urol: Urinary continence outcomes of four years of follow-up and predictors of early and late urinary continence in patients undergoing robot-assisted radical prostatectomy.
Wang Gongxian, First Affiliated Hospital of Nanchang University, published in BJU Int Journal: Transvesical robot-assisted radical prostatectomy: initial experience and surgical outcomes.
Shanghai Changhai Hospital Sun Yinghao published in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key Recommendations Key Recommendation 1: Gao Xu, Sun Yinghao, Shanghai Changhai Hospital: Genetic changes and epigenetic profile of prostate cancer in Asian population.
Sun Yinghao, Shanghai Changhai Hospital, published a study in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key Recommendation 1: Shanghai Changhai Hospital Gao Xu and Sun Yinghao: Asian Human prostate cancer genetic changes and epigenetic map.
Sun Yinghao, Shanghai Changhai Hospital, published a study in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
Key recommendation1: Shanghai Changhai Hospital Gao Xu and Sun Yinghao: Asian Human prostate cancer genetic changes and epigenetic map. The team of Professor Gao Xu and Sun Yinghao from Changhai Hospital drew and analyzed the whole genome, whole transcriptome and DNA methylation data of 208 pairs of tumor tissue samples, and matched the healthy control tissues of Chinese patients with primary prostate cancer.
The genetic and epigenetic profile of prostate cancer in the ethnic population.
The study found that the characteristics of genomic changes in Chinese patients are significantly different from those in western patients.
In particular, it should be pointed out that FOXA1 is highly expressed in the Chinese population (41%), and 18% of tumors ZNF292 and CHD1 are missing.
This research provides a certain reference basis for future drug development and tumor heterogeneity.
Key recommendation 2: 4 articles related to the pathogenesis of prostate cancer published by Chinese scholars in 2020.
The 4 blockbuster studies on the pathogenesis and origin of prostate cancer have all been highly recognized internationally, with a score of 20-30 in journals.
Key recommendation 3: Research on the drug resistance mechanism of potent androgen receptor blockers.
In the research published by clinicians, the focus is mainly on the treatment of new drugs, the drug resistance mechanism and the corresponding targeted therapies for related mechanisms, all of which have been obtained domestically Highly recognized by peers.
These studies provide a new perspective on the mechanism of AR blocker resistance.
Key recommendation 4: Clinical research The West China Hospital team, led by Professor Wei Qiang and Professor Zeng Hao, has been engaged in a series of studies on prostate intraductal carcinoma for a long time.
A series of articles have been published.
Last year’s research results were published in JEU.
This year, the researchers further revealed through a prospective cohort study that for patients undergoing radical prostatectomy, the pathology of preoperative prostate puncture has intraductal cancer and the final surgical pathology Gleason score.
8-10.
Seminal vesicle involvement, pathological stage T3a and other high-risk and highly aggressive characteristics of prostate cancer are related, which can be used to predict the time for high-risk patients without biochemical recurrence after surgery.
Robot-assisted radical prostatectomy has been widely carried out in recent years, but reports of long-term postoperative urinary incontinence are still rare.
Professor Zhang Xu from the General Hospital of the People’s Liberation Army and Professor Liao Limin from the China Rehabilitation Center announced the urinary incontinence of patients 4 years after the robot-assisted radical prostatectomy.
This study is the largest urinary control data on radical treatment of prostate cancer in China so far.
More than 600 patients were included and the follow-up time was close to 4 years.
The results showed that the one-month urinary control rate was 40%, and the three-month urinary control rate reached 60%.
Patients with early postoperative urinary incontinence can gradually recover within one year.
Data show that pelvic lymph node dissection is a risk factor for early postoperative urinary incontinence, advanced age is a risk factor for long-term postoperative urinary incontinence, and intrafascial nerve preservation surgery is still the most important means to improve urinary control.
Key recommendation 5: Clinical research In clinical research, there are two studies in Fudan University Affiliated Cancer Hospital that are worthy of attention: Professor Zhu Yao’s team has carried out the use of 68Ga-PSMA and 18F-FDG PET/CT dual imaging agents in prostate cancer to observe tumors Heterogeneity research.
Professor Ye Dingwei and Professor Dai Bo announced on ESMO the “randomized controlled open-label phase 2 clinical study of newly diagnosed oligometastatic prostate cancer receiving local treatment of the primary tumor”.
This study is the first prospective randomized controlled study to explore the clinical value of radical prostatectomy in patients with newly diagnosed oligometastatic prostate cancer.
A total of 200 patients were enrolled in the study, and they were randomly assigned to the endocrine therapy group (ADT group) and the endocrine therapy combined with the radical treatment group (ADT+RLT group) at 1:1.
The results showed that at a median follow-up of 28 months, 33 patients in the ADT group developed imaging disease progression, 19 patients in the ADT+RLT group developed imaging disease progression, and the median rPFS of the ADT group was 50 months.
The median rPFS of the ADT+RLT group was not reached, and the treatment of the primary tumor of oligometastatic prostate cancer significantly reduced the risk of imaging disease progression in patients (HR=0.
50, P=0.
015).
At present, relevant clinical research in the field of prostate cancer is being extensively carried out in China, including the relevant research of the new androgen receptor antagonist proclutamide, Hc-1119 and PARP inhibitors.
It is believed that the basic and clinical research in the field of prostate will achieve better results in the future.
As a result, a higher level is reached.
